Satellos Bioscience Inc.
Deepah Singh currently serves as Vice President of Finance & Administration at Satellos Bioscience since September 2024. Previously, Deepah held the position of Controller at NervGen Pharma Corp. from August 2018 to August 2024 and at Medicenna Therapeutics Corp. from June 2017 to August 2018. Additional experience includes roles as Assistant Corporate Controller at Magna International, Controller at Kingdsown Canada, and Assistant Controller and General Accountant at YM BioSciences Inc. Deepah's career began as a Financial Accountant at SAP. Deepah is a Certified General Accountant from Ontario and holds a Bachelor of Administrative Studies in Accounting from York University.
This person is not in any teams
Satellos Bioscience Inc.
Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.